<DOC>
	<DOCNO>NCT00702936</DOCNO>
	<brief_summary>The purpose study compare antinflammatory endothelial progenitor cell ( EPC ) mobilize effect Ramipril Telmisartan patient present acute coronary syndrome</brief_summary>
	<brief_title>Telmisartan Versus Ramipril After Acute Coronary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Biochemical evidence myocardial infarction indicate elevation cTnT , presence ECG ischemic change , angiographic evidence primary coronary event , plaque erosion and/or rupture , fissuring , dissection coronary angiography , successful coronary revascularization least one culprit coronary vessel . Age &gt; 80 year , current ACE inhibitor ARB treatment , ejection fraction &lt; 35 % , infarction secondary ischemia due imbalance O2 supply demand , ECG abnormality could affect recognition ST segment shift , recent chronic infective inflammatory disease , malignancy , myocardial infarction , surgery trauma previous month .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>